XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net loss $ (4,180) $ (224)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Loss on disposition of Tantaline 162
Impairment charge 111
Stock-based compensation 908 435
Depreciation and amortization 792 867
Changes in operating assets and liabilities, net of effects of disposition of Tantaline:    
Accounts receivable 1,841 (2,342)
Contract assets 566 368
Inventories (1,921) (1,313)
Income tax receivable 716
Employee retention credit receivable 1,529 (1,529)
Other current assets (47) (301)
Accounts payable (154) 293
Accrued expenses (679) 832
Contract liabilities 866 2,392
Net cash (used in) provided by operating activities (206) 194
Cash flows from investing activities:    
Net cash used in disposition of Tantaline (312)
Deposits from purchaser of MesoScribe assets 597
Purchases of property and equipment (418) (665)
Capitalized patent costs (53)
Net proceeds from sale of assets 10
Net cash used in investing activities (133) (708)
Cash flows from financing activities:    
Proceeds from exercise of stock options 76
Payments of long-term debt (77) (1,772)
Net cash used in financing activities (1) (1,772)
Net decrease in cash and cash equivalents (340) (2,286)
Cash and cash equivalents at beginning of year 14,365 16,651
Cash and cash equivalents at end of year 14,025 14,365
Supplemental disclosure of cash flow information:    
Income taxes paid 8 1
Interest paid 24 8
Non-cash investing and financing activities:    
Loan obtained for new equipment $ 432